Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on the cloud-based software company's stock, anticipating AI-driven gains.
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...
MarketBeat on MSN2d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback